What is Vectorious?
Vectorious Medical Technologies operates at the intersection of advanced engineering and clinical cardiology. The company specializes in the development of implantable sensing technologies that provide continuous, real-time data regarding cardiac function. By moving away from episodic monitoring toward a model of proactive, personalized care, Vectorious aims to reduce hospital readmission rates and improve long-term outcomes for patients with cardiovascular conditions. Their market position is defined by a commitment to high-precision diagnostics that integrate seamlessly into existing clinical workflows, effectively bridging the gap between patient-centric monitoring and physician-led intervention.
How much funding has Vectorious raised?
Vectorious has raised a total of $5M across 1 funding round:
Private Equity
$5M
Private Equity (2015): $5M with participation from RAD BioMed and Global Cardiovascular Innovation Center
Key Investors in Vectorious
RAD BioMed
RAD Biomed is the investment arm of the RAD Bynet group, focusing on early-stage ventures in Israel, particularly in the MedTech, HiTech, Health, Technology, and Energy sectors.
Global Cardiovascular Innovation Center
A specialized organization dedicated to fostering innovation in cardiovascular medicine through strategic partnerships and clinical research support.
What's next for Vectorious?
With this major enterprise-level funding, Vectorious is expected to scale its operational capabilities and expand its clinical trial footprint. The strategic roadmap likely involves refining its sensor architecture to ensure long-term biocompatibility and data accuracy, while simultaneously navigating the regulatory pathways required for broader market adoption. As the company matures, the focus will shift toward commercialization and the integration of its data analytics suite into hospital information systems, ultimately aiming to set a new standard for the management of chronic heart failure on a global scale.
See full Vectorious company page
